Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Czock

Showing results (31-40 of 104) with videos related to

Pageof 11
Sort By:
Therapeutic Drug Monitoring|July 12, 2011
Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremiaClaudia Sommerer, Martin Zeier, David Czock, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of SpironolactoneAndreas D Meid, Camilo Scherkl, Michael Metzner, et al.
BMC Cancer|September 26, 2018
Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasmsKaja Tikk, David Czock, Walter E Haefeli, et al.
Wiener Klinische Wochenschrift|August 5, 2010
[Questionnaire surveying nephrologists on drug dose adjustment in patients with impaired kidney function]Sebastian Maus, Caecilia Holch, David Czock, et al.
European Journal of Haematology|May 7, 2005
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failureJan T Kielstein, Michael Stadler, David Czock, et al.
Contributions to Nephrology|May 15, 2007
Sequential immunosuppressive therapy in progressive IgA nephropathyFranz Maximilian Rasche, Frieder Keller, Lutz von Müller, et al.
European Journal of Clinical Pharmacology|March 26, 2009
Pro-active provision of drug information as a technique to address overdosing in intensive-care patients with renal insufficiencyThilo Bertsche, Martina Fleischer, Johannes Pfaff, et al.
Therapeutic Drug Monitoring|August 30, 2012
Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adultsHeiko Billing, Claudia Sommerer, Thomas Giese, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 4, 2014
Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapyKatja Roos, Daniel Gotthardt, Thomas Giese, et al.
Journal of Nephrology|October 19, 2006
Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathyFranz Maximilian Rasche, Frieder Keller, Lutz von Müller, et al.
Pageof 11

Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Therapeutic Drug Monitoring|July 12, 2011
Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremiaClaudia Sommerer, Martin Zeier, David Czock, et al.
Pharmaceuticals (Basel, Switzerland)|August 29, 2024
Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of SpironolactoneAndreas D Meid, Camilo Scherkl, Michael Metzner, et al.
BMC Cancer|September 26, 2018
Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasmsKaja Tikk, David Czock, Walter E Haefeli, et al.
Wiener Klinische Wochenschrift|August 5, 2010
[Questionnaire surveying nephrologists on drug dose adjustment in patients with impaired kidney function]Sebastian Maus, Caecilia Holch, David Czock, et al.
European Journal of Haematology|May 7, 2005
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failureJan T Kielstein, Michael Stadler, David Czock, et al.
Contributions to Nephrology|May 15, 2007
Sequential immunosuppressive therapy in progressive IgA nephropathyFranz Maximilian Rasche, Frieder Keller, Lutz von Müller, et al.
European Journal of Clinical Pharmacology|March 26, 2009
Pro-active provision of drug information as a technique to address overdosing in intensive-care patients with renal insufficiencyThilo Bertsche, Martina Fleischer, Johannes Pfaff, et al.
Therapeutic Drug Monitoring|August 30, 2012
Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adultsHeiko Billing, Claudia Sommerer, Thomas Giese, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 4, 2014
Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapyKatja Roos, Daniel Gotthardt, Thomas Giese, et al.
Journal of Nephrology|October 19, 2006
Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathyFranz Maximilian Rasche, Frieder Keller, Lutz von Müller, et al.
Pageof 11